These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future. Harikrishnareddy D; Misra S; Upadhyay S; Modi M; Medhi B Rev Neurosci; 2015; 26(2):161-81. PubMed ID: 25720096 [TBL] [Abstract][Full Text] [Related]
32. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Mitsumoto H; Brooks BR; Silani V Lancet Neurol; 2014 Nov; 13(11):1127-1138. PubMed ID: 25316019 [TBL] [Abstract][Full Text] [Related]
33. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials. Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491 [TBL] [Abstract][Full Text] [Related]
34. [Amyotrophic lateral sclerosis, a heterogeneous disorder]. van Es MA; Kruitwagen-van Reenen ET; Schröder CD; Pasterkamp RJ; Veldink JH; van den Berg LH Ned Tijdschr Geneeskd; 2016; 160():A9658. PubMed ID: 26860749 [TBL] [Abstract][Full Text] [Related]
36. Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. Moujalled D; White AR CNS Drugs; 2016 Mar; 30(3):227-43. PubMed ID: 26895253 [TBL] [Abstract][Full Text] [Related]
37. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363 [TBL] [Abstract][Full Text] [Related]
38. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G; Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545 [TBL] [Abstract][Full Text] [Related]
39. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Geevasinga N; Menon P; Özdinler PH; Kiernan MC; Vucic S Nat Rev Neurol; 2016 Nov; 12(11):651-661. PubMed ID: 27658852 [TBL] [Abstract][Full Text] [Related]
40. The Emerging Role of DNA Damage in the Pathogenesis of the C9orf72 Repeat Expansion in Amyotrophic Lateral Sclerosis. Konopka A; Atkin JD Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30322030 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]